Sharon Shechter

868 total citations
22 papers, 372 citations indexed

About

Sharon Shechter is a scholar working on Molecular Biology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Sharon Shechter has authored 22 papers receiving a total of 372 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 9 papers in Oncology and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Sharon Shechter's work include Nuclear Structure and Function (10 papers), Cancer-related Molecular Pathways (6 papers) and Mosquito-borne diseases and control (4 papers). Sharon Shechter is often cited by papers focused on Nuclear Structure and Function (10 papers), Cancer-related Molecular Pathways (6 papers) and Mosquito-borne diseases and control (4 papers). Sharon Shechter collaborates with scholars based in United States, Australia and Italy. Sharon Shechter's co-authors include Laura E. Benjamin, Ori Kalid, Sharon Shacham, Woody Sherman, Dora Toledo Warshaviak, Carole Perruzzi, David R. Thomas, David A. Jans, Rebekah K. O’Donnell and Thuy L. Phung and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Sharon Shechter

22 papers receiving 372 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sharon Shechter United States	11	264	63	49	44	31	22	372
Shinji Kagaya Japan	9	227 0.9×	67 1.1×	52 1.1×	20 0.5×	25 0.8×	14	544
Thierry van de Wetering Poland	10	240 0.9×	117 1.9×	72 1.5×	19 0.4×	25 0.8×	19	399
Samantha Bruno Italy	13	228 0.9×	67 1.1×	69 1.4×	22 0.5×	49 1.6×	40	417
Elke Malenke Germany	9	126 0.5×	82 1.3×	22 0.4×	17 0.4×	28 0.9×	13	303
Robyn L. Schenk Australia	9	277 1.0×	154 2.4×	60 1.2×	57 1.3×	18 0.6×	14	495
George Lominadze United States	8	208 0.8×	27 0.4×	44 0.9×	19 0.4×	40 1.3×	9	484
Emine A. Ercikan-Abali United States	9	224 0.8×	121 1.9×	28 0.6×	75 1.7×	16 0.5×	12	342
J. Hutchins United States	3	260 1.0×	51 0.8×	47 1.0×	10 0.2×	27 0.9×	9	564
James L. Mobley United States	12	152 0.6×	83 1.3×	22 0.4×	15 0.3×	27 0.9×	18	504
Georgi S. Angelov Switzerland	12	155 0.6×	95 1.5×	34 0.7×	24 0.5×	14 0.5×	16	587

Countries citing papers authored by Sharon Shechter

Since Specialization

Citations

This map shows the geographic impact of Sharon Shechter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon Shechter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon Shechter more than expected).

Fields of papers citing papers by Sharon Shechter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharon Shechter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon Shechter. The network helps show where Sharon Shechter may publish in the future.

Co-authorship network of co-authors of Sharon Shechter

This figure shows the co-authorship network connecting the top 25 collaborators of Sharon Shechter. A scholar is included among the top collaborators of Sharon Shechter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharon Shechter. Sharon Shechter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shechter, Sharon, et al.. (2023). Riok1, A Novel Potential Target in MSI-High p53 Mutant Colorectal Cancer Cells. Molecules. 28(11). 4452–4452. 3 indexed citations

Shechter, Sharon, David R. Thomas, & David A. Jans. (2020). Application of In Silico and HTS Approaches to Identify Nuclear Import Inhibitors for Venezuelan Equine Encephalitis Virus Capsid Protein: A Case Study. Frontiers in Chemistry. 8. 573121–573121. 5 indexed citations

DeBono, Aaron, David R. Thomas, Lindsay Lundberg, et al.. (2019). Novel RU486 (mifepristone) analogues with increased activity against Venezuelan Equine Encephalitis Virus but reduced progesterone receptor antagonistic activity. Scientific Reports. 9(1). 2634–2634. 13 indexed citations

Thomas, David R., Lindsay Lundberg, Chelsea Pinkham, et al.. (2018). Identification of novel antivirals inhibiting recognition of Venezuelan equine encephalitis virus capsid protein by the Importin α/β1 heterodimer through high-throughput screening. Antiviral Research. 151. 8–19. 27 indexed citations

Shechter, Sharon, David R. Thomas, Lindsay Lundberg, et al.. (2017). Novel inhibitors targeting Venezuelan equine encephalitis virus capsid protein identified using In Silico Structure-Based-Drug-Design. Scientific Reports. 7(1). 17705–17705. 26 indexed citations

Crochiere, Marsha, Trinayan Kashyap, Ori Kalid, et al.. (2015). Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds. BMC Cancer. 15(1). 910–910. 23 indexed citations

Gerald, Damien, Irit Adini, Sharon Shechter, et al.. (2013). RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcription. Nature Communications. 4(1). 2824–2824. 51 indexed citations

Senapedis, William, Marsha Crochiere, Tami Rashal, et al.. (2013). Abstract B198: Selinexor (KPT-330), a novel Selective Inhibitor of Nuclear Export (SINE) shows marked NF-kB inhibition and significant anticancer activity against Non-Small Cell Lung Cancer (NSCLC).. Molecular Cancer Therapeutics. 12(11_Supplement). B198–B198. 1 indexed citations

Kazerounian, Shiva, Damien Gerald, Minzhou Huang, et al.. (2012). RhoB Differentially Controls Akt Function in Tumor Cells and Stromal Endothelial Cells during Breast Tumorigenesis. Cancer Research. 73(1). 50–61. 40 indexed citations

10.

Gravina, Giovanni Luca, Enrico Ricevuto, Andrea Mancini, et al.. (2012). Abstract 1841: Selective inhibitors of nuclear export (SINE) activate multiple tumor suppressor pathways and kill prostate cancer cells across multiple genotypes in vitro and in vivo. Cancer Research. 72(8_Supplement). 1841–1841. 2 indexed citations

11.

Kalid, Ori, Dora Toledo Warshaviak, Sharon Shechter, Woody Sherman, & Sharon Shacham. (2012). Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors. Journal of Computer-Aided Molecular Design. 26(11). 1217–1228. 62 indexed citations

12.

Landesman, Yosef, William Senapedis, Jean‐Richard Saint‐Martin, et al.. (2012). Abstract 3775: Pharmacokinetic (PK) / pharmacodynamic (PD) and efficacy relationship of selective inhibitors of nuclear export (KPT-SINE). Cancer Research. 72(8_Supplement). 3775–3775. 1 indexed citations

13.

Shacham, Sharon, Giovanni Luca Gravina, Enrico Ricevuto, et al.. (2012). Prelinical evaluation of selective inhibitors of nuclear export (SINE) CRM1 (XPO1) inhibitors in prostate cancer (PrCa).. Journal of Clinical Oncology. 30(15_suppl). e15200–e15200. 3 indexed citations

14.

Senapedis, William, Trinayan Kashyap, Louis Plamondon, et al.. (2012). Abstract 2943: KPT-SINE (Selective Inhibitors of Nuclear Export) induce apoptosis in colon cancer cells in-vitro and in-vivo through nuclear localization of Tumor Suppressor Proteins (TSPs). Cancer Research. 72(8_Supplement). 2943–2943. 1 indexed citations

15.

Kocher, Olivier, Gabriel Birrane, Ayce Yesilaltay, et al.. (2011). Identification of the PDZ3 Domain of the Adaptor Protein PDZK1 as a Second, Physiologically Functional Binding Site for the C Terminus of the High Density Lipoprotein Receptor Scavenger Receptor Class B Type I. Journal of Biological Chemistry. 286(28). 25171–25186. 17 indexed citations

16.

Lapalombella, Rosa, Caroline Berglund, Emilia Mahoney, et al.. (2011). CRM1/XPO1 Represents a Promising Therapeutic Target for Treatment of Chronic Lymphocytic Leukemia. Blood. 118(21). 232–232. 3 indexed citations

17.

Shacham, Sharon, Michael Kauffman, Vincent Sandanayaka, et al.. (2011). Preclinical development of small-molecule CRM1 inhibitors as novel therapy for the treatment of colorectal cancer (CRC).. Journal of Clinical Oncology. 29(4_suppl). 430–430. 2 indexed citations

18.

Shacham, Sharon, Joel G. Turner, Giulio Draetta, et al.. (2010). Preclinical Development of Small-Molecule CRM1 Inhibitors as Novel Therapy for the Treatment of Myeloma and Other Hematological Malignancies. Blood. 116(21). 3012–3012. 3 indexed citations

19.

Iyer, Seema, Mark V. Stevens, Sharon Shechter, et al.. (2009). Akt promotes Endocardial-Mesenchyme Transition. PubMed. 1(1). 2–2. 37 indexed citations

20.

Phung, Thuy L., Rebekah K. O’Donnell, Sharon Shechter, et al.. (2007). Endothelial Akt Signaling Is Rate-Limiting for Rapamycin Inhibition of Mouse Mammary Tumor Progression. Cancer Research. 67(11). 5070–5075. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact